Business
Emergent BioSolutions Reports First Quarter 2025 Financial Results
First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versu
About this update from Emergent Biosolutions Inc.
[{"type":"image","alt":"Emergent BioSolutions","displaySize":"","headline":null,"caption":"Emergent BioSolutions","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/ac51a05701131dc10043a5f2860c099d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8Cci..ShG_us_SMdQyxhzQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ac51a05701131dc10043a5f2860c099d","width":300,"height":36}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior year","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"First Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior year","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"First Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior year","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"First Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior year","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"First Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior year","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"Reaffirmed FY 2025 Guidance","length":27,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":539,"olType":false},{"type":"text","content":"GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2025.","length":172,"tagName":"p"},{"type":"text","content":""Over the past 12 months, we have been executing our multi-year strategic plan to stabilize the company, streamlining operations with an eye toward driving profitability and transforming the company to achieve long-term, sustainable growth built on Emergent’s strengths and unique capabilities," said Joe Papa, president and CEO of Emergent. "We believe our solid first-quarter results are marked by revenues within our guidance range, overall increased profitability margins, increased cash on hand and improved cash flow, further demonstrating that our disciplined approach...